Assessment report Part II – CZECHIA

# ADMINISTRATIVE INFORMATION

|  |  |
| --- | --- |
| CT number  | 2023-505268-12-00 |
| Member State Concerned | Czechia  |
| Title of the study | Multicentrické, randomizované, dvojitě zaslepené, kontrolované klinické hodnocení fáze III k posouzení účinnosti, bezpečnosti a snášenlivosti dvou úvodních podání přípravku COMP360 u účastníků s depresí rezistentní vůči léčbě **A Phase III, multicentre, randomised, double-blind, controlled study to investigate the efficacy, safety, and tolerability of two initial administrations of COMP360 in participants with treatment-resistant depression** |
| Name of sponsors | Compass Pathfinder Limited |
| IMPs (repeat for PR1, PR2…..) | Substance (name/ code): PSILOCYBINE/SUB10158MIG, Marketing authorisation status (MA number, MS where authorised etc): null/nullModified in relation to MA: |

|  |  |
| --- | --- |
| Has Part I been submitted prior to the submission of Part II?*If Yes*Is there already a conclusion on part I?Is the CT already approved in any member state ? | Yes [x]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ]  |

# General information

|  |  |
| --- | --- |
| Is the CT a low-interventional trial?[[1]](#footnote-1) | Yes [ ]  No [x]  |
| First in man [ ] , Phase I [ ] , II [ ] , III [x] , IV[ ]  NA[ ]  |
| Is the CT a cluster trial[[2]](#footnote-2) | Yes [ ]  No [x]  |
| Is the CT intended to be performed in more than one member states?  | Yes [x]  No [ ]  |
| Does the CT involve more than one site in the concerned member states?  | Yes [x]  No [x]  |
| Does the CT include healthy volunteers?  | Yes [ ]  No [x]  |
| Does the CT include female? Male? | Yes [x]  No [ ] Yes [x]  No [ ]  |
| Age groupAdults (18-64 years) Elderly (>= 65 years) < 18 years In UteroPreterm Newborn Infants (up to gestational age < 37 weeks) Newborns (0-27 days) Infants and toddlers (28 days - 23 months) Children (2-11 years) Adolescents (12-17 years) | Yes [x]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ]  |
| Does the CT include vulnerable persons?*If yes*MinorsIncapacitated subjectsPregnant womenBreastfeeding womenSubjects in emergency situationsOther groupsIf yes specify: ............................................................. | Yes [ ]  No [x] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ]  |
| Are there study-specific procedures and/or interventions beyond the drug application? *If yes*Specify: ......dotazníky, videozáznamy, zvukobé záznamy psych.pohovorů...................................... | Yes [x]  No [ ]  |

# Informed Consent fORM

***(Repeat for ICF1, ICR2 ….)***

|  |  |
| --- | --- |
| Date/version of Informed Consent Form  | SIS-ICF\_Main ICF, V 2.0\_12Mar2024 |
| Does the Informed Consent Form contain the correct title of the CT?  | Yes [x]  No [ ]  |
| Does the Informed Consent Form contain placeholder forthe dated signature of the person performing the interview?  | Yes [x]  No [ ]  |
| Does this placeholder indicate the qualification of the person performing the interview  | Yes [x]  No [ ]  |
| Does the Informed Consent Form contain a placeholder forfor the dated signature of the subject for the dated signature of legally designated representative?for the dated signature and name for an impartial witness (in case of a subject is not able to sign (temporarily disabled or illiterate)? | Yes [x]  No [ ]  NA [ ] Yes [x]  No [ ]  NA [ ] Yes [x]  No [ ]  NA [ ]  |
| Does the Informed Consent Form contain a placeholder for the assent from minor (capable of forming an opinion) | Yes [x]  No [ ]  NA [ ]  |
| Does the subject or the legally designated representative declare that the information is understood? | Yes [x]  No [ ]  NA [ ]  |
| Does the subject or the legally designated representative confirm whether a copy of the Informed Consent Form (or the record) has been retained? | Yes [x]  No [ ]  NA [ ]  |
| Does the subject or the legally designated representative declare that the information is understood? | Yes [x]  No [ ]  |
| *Additional items may be added according to national requirements*For exampleDoes the subject or the legally designated representative confirm whether a copy of the Informed Consent Form (or the record) has been retained?  | Yes [x]  No [ ]  |

**Conclusion**

If all points are addressed Yes): The Inform Consent Form fulfils the conditions in art. 29, 1.

If not

**Questions/queries:**

# Written Information

|  |  |
| --- | --- |
| Is the Information sheet sufficiently comprehensive, concise, clear, relevant, and understandable to a layperson? | Yes [x]  No [ ]   |
| Does the information sheet describe adequately nature, objectives, benefits, implications, risks, and inconveniences, of the clinical trial? | Yes [x]  No [ ]   |
| Does the information sheet adequately describe the subject's rights and guarantees regarding his or her protection, in particular his or her right to refuse to participate and the right to withdraw from the clinical trial at any time without any resulting detriment and without having to provide any justification ?Does the information sheet adequately explain that withdrawal of the informed consent will not affect the results of activities already carried out and the use of data obtained, based on informed consent, before its withdrawal? | Yes [x]  No [ ]  Yes [x]  No [ ]   |
| Does the information sheet adequately describe the conditions under which the clinical trial is to be conducted, including the expected duration of the subject's participation in the clinical trial? | Yes [x]  No [ ]   |
| Does the information sheet adequately describe the possible treatment alternatives, the follow-up measures if the participation of the subject in the clinical trial is discontinued Post trial treatment options | Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  NA [ ]   |
| Does the information sheet provide information about the damage compensation according to national law of concerned member state*Further detailed points to be filled in at a national level**If NA*Does the information sheet adequately inform that no particular arrangements for damage compensation are in place | Yes [x]  No [ ]  NA [ ] Yes [ ]  No [ ]   |
| Does the information sheet provide the EU trial number information about the availability of the clinical trial results (that the summary of the results of the clinical trial and a summary presented in terms understandable to a layperson will be made available in the EU database)  | Yes [x]  No [ ]  Yes [ ]  No [ ]   |
| Does the information sheet provide adequate information aboutplanned personal data collection and processing Does the information sheet provide adequate information about planned collection, storage and future use of biological samples? *Further detailed points must filled in by member states at national level* (in accordance with Regulation (EC) No 45/2001 and **national data protection legislation** implementing Regulation (EU) 2016/679, respectively) | Yes [ ]  No [ ]  Yes [ ]  No [ ]   |

|  |  |
| --- | --- |
| In the case of a trial with minors. Is there Informed Consent documents adequately paying attentions to the information needs of these subjects? In the case of a trial with incapacitated subjects. Is there Informed Consent documents adequately paying attentions to the information needs of these subjects? In the case of a trial in an emergency situationAre there Informed Consent documents to obtain consent from the subject and/or legally designated representative to continue the participation of the subject in the CT after the intervention? | Yes [ ]  No [ ]  Yes [ ]  No [ ]  Yes [ ]  No [ ]   |

**Conclusion**

If all points are addressed Yes: The written information fulfils the conditions in art. 28 and 29

If not

**Questions/queries:**

# Protection of personal Data

|  |  |
| --- | --- |
| Has a statement been submitted by the sponsor or his or her representative that data will be collected and processed in compliance with Regulation (EC) No 45/2001 and **national data protection legislation** implementing Regulation (EU) 2016/679, respectively*Further detailed points must filled in by member states at national level* For exampleAre the rules for the collection, storage and future use of biological samples of the subject fulfilled?Is the procedure to pseudonymise the data correct?Are Initials omitted?Is there no placeholder for the complete birthday?Will the coding number maintained in the hand of the investigator or of a trustee?Is described how long the data will be stored?Is there a comprehensive description of the aims and scope of data collection?Is there an indication, whether the data will be transferred to a so called “third party country” with a reduced level of data protection? | Yes [ ]  No [ ]  Yes [ ]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [ ]  No [x]  Yes [x]  No [ ]  Yes [x]  No [ ]   |
| Will the subject (or his or her legally designated representative) be asked to consent to the use of his or her data and/or biological samples outside the protocol of the clinical trial for other scientific purposes?*If Yes*Will the subject be informed that this consent may be withdrawn at any time by the subject or his or her legally designated representative? | Yes [ ]  No [x]  Yes [ ]  No [ ]   |

**Questions/queries:**

# Compensation

|  |  |
| --- | --- |
| Is there no undue influence, including that of a financial nature, exerted on subjects to participate in the clinical trialIn trials with incapacitated subjects, minors, pregnant or breastfeeding subjects: Are no incentives or financial inducements given to the subjects or their legally designated representatives, except for compensation for expenses and loss of earnings directly related to the participation in the clinical trial; | Yes [ ]  No [x]  Yes [ ]  No [x]   |

**Questions/queries:**

# Recruitment

|  |  |
| --- | --- |
| Is the procedure for inclusion of subjects described in detail in the protocol or a separate document Is clearly described of what the first act of recruitment is?Is the recruitment of subjects planned to be done through advertisementIf yes: Have copies of the advertising material been submitted, including any printed materials, and audio or visual recordings. Has an outline of the procedures proposed for handling responses to the advertisement been submitted? Have copies of communications used to invite subjects to participate in the clinical trial been submitted?Have arrangements for information or advice to the respondents found not to be suitable for inclusion in the clinical trial been described?Does the person performing the interview has the required qualification according to the law of concerned member statesAre the arrangements for recruitment of subjects adequate? | Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ] Yes [ ]  No [ ]  Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ] Yes [ ]  No [ ]  |

**Questions/queries:**

# SUITABILITY OF THE INVESTIGATOR

|  |  |
| --- | --- |
| 1. MUDr. Martin Brunovský, Ph.D.
2. MUDr. Alexander Nawka, Ph.D.
3. MUDr. Mgr. Marek Perez, Ph.D., MBA
4. MUDr. Tomáš Páleníček, Ph.D.
5. MUDr. Luboš Janů, Ph.D.
6. MUDr. Slavomír Pietrucha
 |  |
| Is there an informative CV?Is previous experience obtained from work with clinical trials described?Is previous experience obtained from work with patient care described?Have certificates describing adequate ICH/GPV training been submitted?Has a financial disclosure been submitted?Have institutional affiliations, that might influence the impartiality of the investigators been presented?*Further detailed points may be filled in by member states at national level* For exampleIs the investigator qualified in accordance with national Low?*(medical doctor as defined in national law, or a person following a profession which is recognised in the Member State concerned)*  | Yes [x]  No [ ]  Yes [x]  No [ ] Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [ ]  No [ ]   |

**Conclusion**

**Cistovicka 249/11, Repy (Brunovsky Martin )
Krizikova 264/22, Karlin (Nawka Alexander )
Opavska 962/39 (Perez Marek )
Topolova 748 (Palenicek Tomas )
Sumavska 2, Vychodni Predmesti (Janu Lubos )
Bozeny Jandlove 2132/3, Modrany (Pietrucha Slavomir )**

**Reason:**

# SUITABILITY OF THE FACILITIES

|  |  |
| --- | --- |
| Has a list of the planned clinical trial sites with name and position of the principal investigators and the planned number of subjects at the sites been submitted?1. Psyon s.r.o., Čistovická 249/11, Praha
2. INEP medical s.r.o., Křížkova 264/22, 186 00 Praha
3. MPMeditrine s.r.o., Opavská 962/39, 708 00 Ostrava
4. Národní ústav Duševního zdraví, Topolova 748, 250 67 Klecany
5. A-Shine s.r.o., Šumavská 2, 301 00 Plzeň
6. Neuroterapie KH s.r.o, Boženy Jandlové 2132/3, 143 00 Praha

Has a written statement been submitted describing the suitability of the clinical trial sites adapted to the nature and use of the investigational medicinal product? (issued by the head of the clinic/institution at the clinical trial site or by some other responsible person, according to the system in the Member State concerned)Does this statement adequately describe the suitability of facilities, the equipment, the human resources the expertise of the site, | Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [x]  No [ ]   |

**Conclusion**

Cistovicka 249/11, Repy (Brunovsky Martin )
Krizikova 264/22, Karlin (Nawka Alexander )
Opavska 962/39 (Perez Marek )
Topolova 748 (Palenicek Tomas )
Sumavska 2, Vychodni Predmesti (Janu Lubos )
Bozeny Jandlove 2132/3, Modrany (Pietrucha Slavomir )

**Reason:**

# PROOF OF INSURANCE COVER OR INDEMNIFICATION

|  |  |
| --- | --- |
| Is the arrangement for damage compensation in accordance to **national law**?*Further detailed points must be filled in at the national level*  | Yes [x]  No [ ]   |

**Questions/queries:**

# FINANCIAL AND OTHER ARRANGEMENTS

|  |  |
| --- | --- |
| Is there a description confirming adequate financing of the clinical trial is ensured?Are financial transactions and compensation paid to subjects adequate?Are financial transactions and compensation paid to the investigator/site for participating in the clinical trial adequate?Are any other agreement between the sponsor and the site adequate? | Yes [x]  No [ ]  Yes [x]  No [ ]  Yes [ ]  No [ ]  NA [x] Yes [ ]  No [ ]  NA [x]  |

**Questions/queries:**

# LIST OF questions TO THE SPONSOR/

#  Assesment of the Sponor´s Response

|  |  |
| --- | --- |
| Are all queries resolved?If not specify:..........................................................................................  | Yes [ ]  No [ ]   |

# FINAL Decision

|  |  |
| --- | --- |
| The Clinical trial is approvableThe Clinical trial is not approvableThe Clinical trial is approvable subjects to conditions  | [x] [ ] [ ]  |

**In case of approval**

**The approval is valid for the following trial sites and investigators**

1. MUDr. Martin Brunovský, Ph.D., Psyon s.r.o., Čistovická 249/11, Praha
2. MUDr. Alexander Nawka, Ph.D., INEP medical s.r.o., Křížkova 264/22, 186 00 Praha
3. MUDr. Mgr. Marek Perez, Ph.D., MBA, MPMeditrine s.r.o., Opavská 962/39, 708 00 Ostrava
4. MUDr. Tomáš Páleníček, Ph.D., Národní ústav Duševního zdraví, Topolova 748, 250 67 Klecany
5. MUDr. Luboš Janů, Ph.D., A-Shine s.r.o., Šumavská 2, 301 00 Plzeň
6. MUDr. Slavomír Pietrucha, Neuroterapie KH s.r.o, Boženy Jandlové 2132/3, 143 00 Praha

**List of members of the ethic committee participating in the decision**

MUDr. Jindřiška Burešová (chairman)

doc. MUDr. Jiřina Zapletalová, Ph.D.

prof. MUDr. et Mgr. Jiří Minařík, Ph.D.

MUDr. Libor Kvapil

MUDr. Josef Srovnal, Ph.D.

Anna Holá

MUDr. et PhDr. Lenka Hansmanová, Ph.D.

PharmDr. Tomáš Anděl, Ph.D.

doc. MUDr. Libuše Stárková, CSc.

prof. MUDr. Karel Indrák, DrSc.

MUDr. Karel Cwiertka, Ph.D.

MUDr. Jan Strojil, Ph.D.

Iveta Sudolská

Věra Bartlová

**List of documents on the basis of which the decision was made**

1. K2\_HH Factsheet, v 4.0, 7 Dec 2023
2. K2\_Images, v3.0\_1 Feb 2024
3. K2\_LB BRV\_Tnoversion
4. K2\_LB BV\_Tnoversion
5. K2\_LB MoA\_Tnoversion
6. K2\_LB MV, Videos v1.0, 04-Oct-2022
7. K2\_LB PE\_Tnoversion
8. K2\_LB RCH\_Tnoversion
9. K2\_MP Consent Navigator, 19-May-2023 v1.0 Czech
10. K2\_MP Notif CfT
11. K2\_MP Patient Portal, Protocol v3.0, 13-Feb-2023
12. K2\_PAG Copy, v3.0, 1 Feb 2024
13. K2\_PFS
14. K2\_PIS
15. K2\_PL, V3.0\_ 12MAY2023
16. K2\_PN, v5.0, 21Jul2021
17. K2\_Poster, V3.0, 06MAR2023
18. K2\_Print Ads Copy, v2.0, 06OCT2022
19. K2\_Print Ads, V2.0\_27SEP2022(2
20. K2\_QSG, v2.0 15Jul2022
21. K2\_Telephone PS Script, V2.0 10. listopadu 2023
22. K2\_Web text for sites, v3.0\_1Feb2024
23. K2\_Website Copy, v4.0\_1Feb2024
24. L1\_SIS-ICF\_GDPR ICF, V2.0\_12. března 2024
25. L1\_SIS-ICF\_Main ICF, V 2.0\_12Mar2024
26. L1\_SIS-ICF\_Medical Record RF, V1.0, 18Oct2023
27. L1\_SIS-ICF\_Optional Biomarker, V 3.0, 21Mar2023
28. L1\_SIS-ICF\_Pre-Screening ICF, V 2.0, 21. března 2023
29. L2\_Subject Card. verze 2.0, 17. března 2021
30. M1\_CV PI Nawka\_INEP Medical, 16 Oct 2023
31. M1\_CV PI Pietrucha\_Neuroterapie KH, 21 Mar 2024
32. M1\_CV PI\_ Janu\_A-Shine, 12 Oct 2023
33. M1\_CV\_PI Brunovsky\_PSYON, 25 Oct 2023
34. M1\_CV\_PI Palenicek, 2 Nov 2023
35. M1\_CV\_PI\_Perez\_MPMeditrine, 28 Mar 2023
36. M2\_ DoI\_PI Nawka\_INEP Medical, 12 Oct 2023
37. M2\_DoI\_PI Brunovsky\_PSYON, 18 Oct 2023
38. M2\_DoI\_PI Perez\_MPMeditrine, 28 Mar 2024
39. M2\_DoI\_PI\_Janu\_A-Shine, 12 Oct 2023
40. M2\_DoI\_PI\_Palenicek\_NUDZ, 11 Oct 2023
41. M2\_PI DoI\_PI Pietrucha\_Neuroterapie KH, 21 Mar 2024
42. N1\_Site Registration\_A-Shine, 19 Nov 2021
43. N1\_Site Registration\_INEP Medical, 28 Mar 2018
44. N1\_Site Registration\_MPMeditrine, 19 Nov 2014
45. N1\_Site Registration\_Neuroterapie KH, 17 Dec 2020
46. N1\_Site Registration\_PSYON, 26 Aug 2022
47. N1\_Site Suitability\_A-Shine, 3 Nov 2023
48. N1\_Site Suitability\_INEP Medical, 17 Oct 2023
49. N1\_Site Suitability\_MPMeditrine, 28 Mar 2024
50. N1\_Site Suitability\_Neuroterapie, 21 Mar 2024
51. N1\_Site Suitability\_NUDZ, 24 Oct 2023
52. N1\_Site Suitability\_PSYON, 25 Oct 2023
53. O1\_Insurance certificate, 13 Dec 2023
54. O2\_Insurance Policy\_Amendment 1, 10 Aug 2023
55. O2\_Insurance Policy
56. P1\_Compensation for pts, CZ v1\_19Oct2023
57. R1\_Compl National Data Protect, 3 Oct 2023
58. S1\_Compl Use Bio samples, 28 Jan 2022
59. K1\_Recruit-ICF procedure, V 3.0, 5.5.2022
60. K2\_Advocacy FS, 9 Jan 2024
61. K2\_Brochure, 9 Jan 2024
62. K2\_Caregiver Info, 12 May 2023
63. K2\_COMP6BQ, 9 Aug 2022
64. K2\_COMPEQ
65. K2\_COMPES
66. K2\_Core
67. K2\_Digital MC, 12 Jan 2024
68. K2\_Flyer, 12 May 2023
1. If yes – other demands for damage compensation, cfr. Art. 76 [↑](#footnote-ref-1)
2. If yes – other demands for informed consent, cfr. Art. 30 [↑](#footnote-ref-2)